NCT06328127 Positive Psychology Intervention for Hematopoietic Stem Cell Transplantation Survivors
| NCT ID | NCT06328127 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Brigham and Women's Hospital |
| Condition | Hematopoietic Stem Cell Transplant |
| Study Type | INTERVENTIONAL |
| Enrollment | 400 participants |
| Start Date | 2024-12-17 |
| Primary Completion | 2029-05-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 400 participants in total. It began in 2024-12-17 with a primary completion date of 2029-05-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This randomized clinical trial is evaluating the impact of a positive psychology intervention (PATH) on anxiety symptoms, depression symptoms, and quality of life in survivors of hematopoietic stem cell transplant (HSCT) compared to usual care.
Eligibility Criteria
Inclusion Criteria: * Adult patients (aged 18 years and older) undergoing allogeneic HSCT and are approaching 100-days post-HSCT * Ability to speak, read, and respond to questions in English or Spanish to complete study procedures * Access to a basic telephone Exclusion Criteria: * Patients who underwent allogeneic HSCT for benign hematologic conditions * Patients with severe psychiatric or cognitive conditions, such as dementia, determined by their transplant oncologist to make them unable to provide informed consent or comply with study procedures
Contact & Investigator
Hermioni Amonoo, MD, MPP, MPH
PRINCIPAL INVESTIGATOR
Brigham and Women's Hospital
Frequently Asked Questions
Who can join the NCT06328127 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hematopoietic Stem Cell Transplant. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06328127 currently recruiting?
Yes, NCT06328127 is actively recruiting participants. Contact the research team at hermioni_amonoo@dfci.harvard.edu for enrollment information.
Where is the NCT06328127 trial being conducted?
This trial is being conducted at Tampa, United States, Boston, United States, Durham, United States.
Who is sponsoring the NCT06328127 clinical trial?
NCT06328127 is sponsored by Brigham and Women's Hospital. The principal investigator is Hermioni Amonoo, MD, MPP, MPH at Brigham and Women's Hospital. The trial plans to enroll 400 participants.